肠道病毒71型灭活疫苗上市后安全性主动与被动监测

doi:10.3969/j.issn.2095-9400.2020.02.013

Abstract
Figure/Table
References (0)
Related Citation (7)

Download: PDF (1361 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To evaluate post-marketing safety of enterovirus 71 inactivated vaccine (EV71 vaccine), and provide scientific basis for formulating immunization strategy. Methods: The adverse reactions of EV71 vaccine in Wenzhou city were collected by a combination of active and passive surveillance methods and analyzed statistically by SPSS23.0 software. Results: The incidence of adverse reactions of EV71 vaccine was 4.2/10 000 doses in passive surveillance, of which the incidence of abnormal reactions was 0.5/10 000 doses. The incidence of adverse reactions was 156.7/10 000 doses in active surveillance, of which the incidence of abnormal reactions was 12.0/10 000 doses. The incidence of adverse reactions and abnormal reactions in active surveillance were both higher than those in passive surveillance, with statistical difference (P<0.05). Active surveillance showed that adverse reactions mainly occurred within 30 min-3 d (62.4%) after immunization, and the main clinical symptom was fever. With the increase in age, the incidence of adverse reactions showed a downward trend (P<0.05). There was a significant difference in the rate of adverse reactions between different genders, i.e. higher in women than in men (P<0.05). Conclusion: The incidence of adverse reactions of EV71 vaccine was low, the symptoms were common and mild, and the overall safety was good. Active surveillance was more sensitive and accurate than passive surveillance.

Key words： hand foot mouth disease EV71 inactivated vaccine safety active and passive surveillance

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Lingping
	SUN Xiaoyu
	WEI Jingjiao
	ZHENG Xiaochun
	LI Wancang
	WANG Zhigang

URL:

https://xb.wmu.edu.cn/EN/10.3969/j.issn.2095-9400.2020.02.013 OR https://xb.wmu.edu.cn/EN/Y2020/V50/I2/149

[1] 杨芳, 于石成, 张菊英, 等. 2008～2011年我国大陆地区重症手足口病流行特征分析[J]. 疾病监测, 2013, 28(11): 888-893.
[2] 邵俊杰, 王嘉瑜, 滕峥, 等. 2009～2011年上海市手足口病流行病学和病原学特征[J]. 微生物与感染, 2013, 8(4): 227-233.
[3] WALDMAN E A, LUHM K R, MONTEIRO S A, et al. Surveillance of adverse effects following vaccination and safety of immunization programs[J]. Rev Saude Publica, 2011 , 45(1): 173-184.
[4] 食药讯. 全球首个肠道病毒71型灭活疫苗在我国获批上市[J]. 首都食品与医药, 2016, 5: 43.
[5] GRIFFIN M R, BRAUN M M, BART K J. What should an ideal vaccine postlicensure safety system be?[J]. Am J Public Health, 2009, 99 Suppl 2: S345-350.
[6] 蔡婷, 杨羽, 王亚丽, 等. 疫苗上市后安全性主动监测模式分析[J]. 中国药物警戒, 2017, 14(8): 464-469.
[7] 王雷, 王四全, 胡樱, 等. 湖北省2016—2017年肠道病毒71型灭活疫苗上市后安全性[J]. 中国疫苗和免疫, 2018, 24(4): 471-474.
[8] 张量智, 陈恒, 李蕾, 等. 成都市肠道病毒71型灭活疫苗上市后安全性监测分析[J]. 现代预防医学, 2018, 45(16): 3019-3022.
[9] 杜进发, 钟革, 陆伟才, 等. 2016—2017年广西肠道病毒71型灭活疫苗疑似预防接种异常反应监测结果分析[J]. 应用预防医学, 2018, 24(5): 384-386.
[10] 许涤沙, 李克莉, 武文娣, 等. 中国2016年疑似预防接种异常反应监测数据分析[J]. 中国疫苗和免疫, 2018, 24(3): 299-309, 322.
[11] 徐昊. 卢湾区儿童预防接种后不良事件监测方法探索[D]. 上海: 复旦大学, 2013.
[12] World Health Organization. Global vaccine safety blueprint [EB/OL]. (2012-02) [2019-03-10]. http://www.who.int/vaccine_safety/en/.
[13] 武文娣, 刘大卫. 疫苗上市后安全性主动监测及其流行病学研究方法[J]. 中国疫苗和免疫, 2016, 22(2): 221-229, 237.
[14] 王一军, 潘海燕, 臧霞, 等. 肠道病毒71型灭活疫苗(Vero细胞)安全性分析[J]. 公共卫生与预防医学, 2019, 30(1): 10-13.
[15] 陆云峰. 2017年两种市场主流EV71疫苗的安全性观察研究[J]. 基层医学论坛, 2019, 23(5): 693-695.
[16] 张文静, 时念民, 张彦利, 等. 国产EV71灭活疫苗上市后大人群接种安全性分析[J]. 中国公共卫生, 2019, 35(4): 385-387.
[17] 许涤沙, 刘大卫. 轮状病毒疫苗安全性: 世界卫生组织美洲区上市后监测[J]. 中国疫苗和免疫, 2011, 17(4): 384-385.
[18] 安志杰, 刘艳, 廖巧红, 等. 肠道病毒71型灭活疫苗使用技术指南[J]. 中国疫苗和免疫, 2016, 22(4): 458-464.
[19] 许玉洋, 许二萍, 李倩, 等. 国产乙脑灭活疫苗安全性主动监测结果分析[J]. 浙江预防医学, 2016, 28(6): 600-603.
[20] 杨佳平, 李晓军, 杨兴堂, 等. 上海市宝山区老年人接种23价多糖肺炎球菌疫苗后安全性观察[J]. 中国农村卫生事业管理, 2017, 37(9): 1064-1066.
[21] 石晓娟, 周路平, 周莉薇, 等. 国产Sabin株脊髓灰质炎灭活疫苗接种后的安全性调查[J]. 中国疫苗和免疫, 2017, 23(4): 383-386.
[22] 张国民, 张振国, 张晓曙, 等. 甲型H1N1流行性感冒疫苗接种安全性研究[J]. 中国疫苗和免疫, 2012, 18(6): 511-514.